Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CellDesign Inc.

This article was originally published in Start Up

Executive Summary

Current cellular models for drug discovery can be notoriously unreliable, both for their predictive power and their sustainability. Cells derived from human progenitor stem cells can provide homogeneity over countless experiments, but working with them remains a complex scientific art. By industrializing production of stem cell-derived cell model systems, CellDesign Inc. intends to capture a chunk of the existing $1.5 billion market for cellular model systems and grow it through sales of easy-to-use kits for deriving everything from human fat cells to Alzheimer's disease-ridden neurons.
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091771

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel